Ekocorp

Ekocorp FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Ekocorp (EKOCORP.NL) as of Oct 22, 2026 is 117.55 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 139.84 % — a change of -15.94% (lower).

FCF Conversion

117.55 %

YoY

-15.94%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Ekocorp is 2020 117.55 % . FCF Conversion Rate (FCF/EBITDA) of Ekocorp was 2019 139.84 % . It decreases by -15.94% lower compared to the previous year.

The Ekocorp FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
-491.00 NGN
Jan 1, 2016
67.18 NGN
Jan 1, 2017
5.01 NGN
Jan 1, 2018
4.05 NGN
Jan 1, 2019
139.84 NGN
Jan 1, 2020
117.55 NGN
The Ekocorp FCF Conversion history
YEARFCF ConversionYoY
117.55 %-15.94%
139.84 %+3,353.82%
4.05 %-19.25%
5.01 %-92.54%
67.18 %-113.68%
-491.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ekocorp Stock analysis

What does Ekocorp do? Ekocorp PLC provides healthcare services through its segments including standalone facilities, capitation models, and strategic business units such as general outpatients, nursing, intensive care, medical, obstetrics and gynaecology, paediatrics, radiology, and surgery. The company offers specialized medical services like dietician, diabetic nurse educator, foot care specialist, and consultant ophthalmologist. Its consultant services encompass general surgery, orthopaedic surgery, grammatology, otorhinolaryngology, audiology, speech therapy, dental surgery, ophthalmology, radiology, physical medicine (Physiotherapy), endoscopy, anaesthesia, obstetrics and gynaecology, radiotherapy, and oncology. Ekocorp also provides immunological screening services including thyroid antibodies, thyroid adrenal anti-nuclear antibodies, and paediatric endocrinology. The firm targets patients seeking specialized medical care and preventive health services. Its services are delivered through its healthcare delivery model focused on standard medical care and anchor services. Ekocorp's strategic business units serve diverse patient needs across various medical specialties. The company's offerings include both outpatient and inpatient care through its structured segments. Ekocorp PLC's revenue streams come from medical service fees charged to patients and healthcare providers. The company generates income through its consultant services, specialized medical care, and immunological screening services. Its business model relies on delivering high-quality healthcare services across multiple specialties to a broad patient base. The firm's segments operate under a unified healthcare delivery framework that supports its service offerings. Ekocorp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ekocorp stock

FCF Conversion Rate (FCF/EBITDA) of Ekocorp is 117.55 % in 2020.

FCF Conversion Rate (FCF/EBITDA) of Ekocorp changed from 139.84 % to 117.55 %, representing a -15.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Ekocorp since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Ekocorp with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ekocorp

All Key Metrics — Ekocorp